Abstract
Gastric inhibitory polypeptide (GIP) and truncated glucagon like peptide-1 (tGLP-1) are potent gastrointestinal insulinotropic factors (incretin), mostly released after a meal or ingestion of glucose in man and animals. To investigate whether sulfonylurea (SU) affects the secretion of incretin, the modulation of plasma GIP and tGLP-1 levels following glucose ingestion in non-insulin-dependent diabetic type 2 patients with or without SU therapy was studied. A 75-g oral glucose tolerance test (OGTT) was carried out on 9 healthy subjects (controls) and 18 patients with non-obese type 2, 9 of whom were treated by diet alone (NIDDM-diet) and the other 9 with SU (glibenclamide 2.5 mg or gliclazide 40 mg) once a day (NIDDM-SU). Plasma GIP was measured by radioimmunoassay (RIA) with R65 antibody, and GLP-1 was measured by RIA with N-terminal-directed antiserum R1043 (GLP-1NT) and C-terminal-directed antiserum R2337 (GLP-1CT). Following OGTT, plasma glucose, GIP, GLP-1NT, and GLP-1CT in type 2 patients increased more markedly than in controls, despite the lower response of insulin. However, there were no significant differences in plasma levels of these peptides between the NIDDM-diet and NIDDM-SU groups. Therefore, it is unlikely that SU is involved in the high response of GIP and GLP-1s to OGTT in type 2 patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ricketts H, Wildbeger HL, Schmid H, Long-term studies of sulfonylureas in totally depancreatectomized dogs. Ann NY Acad Sci 71:170–176, 1957
Mandarino LJ, Gerich JE, Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Diabetes Care 7 (Suppl 1):89–94, 1984
Hatao K, Kaku K, Matsuda M, Tsuchiya M, Kaneko T, Sulfonylurea stimulates liver fructose-2,6-bisphoshate formation in proportion to its hypoglycemic action. Diabetes Res Clin Pract 1:49–53, 1985
Hirota M, Hashimoto M, Hiratuka M, Ohboshi C, Yoshimoto S, Yano M, Mizuno A, Sima K, Alterations of plasma immunoreactive glucagon-like peptide-1 behavior in non-insulin-dependent diabetics. Diabetes Res Clin Pract 9:179–185, 1990
Orskov C, Jeppesen J, Madsbad S, Holst JJ, Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415–423, 1991
Fukase N, Igarashi M, Takahashi H, Manaka H, Yamatani K, Daimon M, Tominaga M, Sasaki H, Hypersecretion of truncated glucagon-like peptide-1 and astric inhibitory polypeptide in obese patients. Diabetic Med 10:44–49, 1993
Malaisse WJ, Hubinont C, Lebrun P, Herchuelz A, Couturier E, Deleers M, Malaisse-Lagae F, Sener A, Mode of action of hypoglycaemic sulfonylureas in the pancreatic B cell: coinciding and conflicting views. In: Serrano-Rios M, Krall LP (eds) Clinical and pharmacological activities of sulfonylurea drugs. Excerpta Medica, Amsterdam, p 24, 1983
Cataland S, Crockett SE, Brown JC, Mazzaferri EL, Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab 39:223–228, 1974
Kreymann B, Williams G, Ghatei MA, Bloom SR, Glucagon-like peptide-1 7–36: physiological incretin in man. Lancet 2:1300–1304, 1987
Mojsov S, Weir GC, Habener JF, Insulinotropin: glucagon-like peptide-1 (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616–619, 1987
Brown JC, Dryburgh JR, Ross RA, Dupre J, Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 31:487–532, 1975
Krarup T, Holst JJ, The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Peptides 9:35–46, 1984
Takahashi H, Manaka H, Suda K, Fukase N, Tominaga M, Sasaki H, Kawai K, Ohashi S, Radioimmunoassay for glucagon-like peptide-1 in human plasma using N-terminal and C-terminal directed antibodies: a physiologic insulinotropic role of GLP-1 (7–36 amide). Biomed Res 11:99–108, 1990
Nishino T, Kodaira T, Shin S, Glucagon radioimmunoassay with use of antiserum to glucagon C-terminal fragment. Clin Chem 27:1690–1697, 1981
Harris V, Faloona GR, Unger RH, Glucagon. In: Jaffe BM, Behrman HR (eds) Methods of hormone radioimmunoassay. Academic Press, New York, pp 643–656, 1979
Ross SA, Brown JC, Dupre J, Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26:525–529, 1977
Ebert R, Frerichs H, Creutzfeldt W, Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose tolerance. Eur J Clin Invest 9:129–135, 1979
Creutzfeldt W, Ebert R, Willems B, Frederichs H, Brown JC, Gastric inhibitory polypeptide (GIP) and defective feedback control on serum levels. Diabetologia 14:15–24, 1978
Creutzfeldt W, Ebert R, Release of gastric inhibitory polypeptide (GIP) to a test meal under normal and pathological conditions in man. In: Bajaj JE (ed) Diabetes Excerpt Med Int Congr Ser 413. Excerpta Medica, Amsterdam, pp 63–75, 1977
Coxe JS, O'Dorisio TM, Cataland S, Crockett SE, Gastric inhibitory polypeptide hypersecretion in diabetes mellitus: effect of sulfonylurea treatment. J Clin Endocrinol Metab 52:1002–1005, 1980
Muller WA, Faloona GR, Aguilar-Parada E, Unger RH, Abnormal alpha cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med 283:109–115, 1970
Ogawa A, Suda K, Wakasugi K, Yamatani K, Sasaki H, Hoshikawa T, Kameyama J, Tsukamoto M, Evaluation of plasma levels of glucagon related peptides in consideration for their size heterogeneity. Clin Endocrinol 34:81–88, 1986
Kobric M, Brown JC, Ross SA, Dupre J, Exaggerated rise in plasma glucagon-like immunoreactivity after I. V. gastric inhibitory polypeptide in streptozotocin diabetic rats. Clin Res 22:751A, 1974
Suda K, Takahashi H, Fukase N, Manaka H, Tominaga M, Sasaki H, Distribution and molecular forms of glucagon-like peptide in the dog. Life Sci 45:1793–1789, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fukase, N., Manaka, H., Sugiyama, K. et al. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Acta Diabetol 32, 165–169 (1995). https://doi.org/10.1007/BF00838486
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00838486